ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

KERX Keryx Biopharmaceuticals, Inc. (delisted)

3.36
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Keryx Biopharmaceuticals, Inc. (delisted) NASDAQ:KERX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.36 3.10 3.35 0 01:00:00

KERX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Keryx Biopharmaceuticals, ...

09/09/2016 2:57pm

PR Newswire (US)


Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Keryx Biopharmaceuticals, Inc. (delisted) Charts.

NEW YORK, Sept. 9, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) securities February 25, 2016 and August 1, 2016.

The Law Offices of Vincent Wong logo

Click here to learn about the case: http://www.wongesq.com/pslra/keryx-biopharmaceuticals. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company was experiencing production-related difficulties in converting API to finished drug product; (2) that the issue was resulting in decreased production yields of finished drug product; (3) that, as a result, the Company would, and did exhaust its reserve of finished drug product; and (4) that, as a result of the foregoing, Defendants' statements about Keryx's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Keryx Biopharmaceuticals you have until October 3, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/keryx-biopharmaceuticals.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

Logo - http://photos.prnewswire.com/prnh/20140904/143045

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kerx-investor-alert-the-law-offices-of-vincent-wong-reminds-investors-of-a-class-action-involving-keryx-biopharmaceuticals-inc-and-a-lead-plaintiff-deadline-of-october-3-2016-300325483.html

SOURCE The Law Offices of Vincent Wong

Copyright 2016 PR Newswire

1 Year Keryx Biopharmaceuticals, Inc. (delisted) Chart

1 Year Keryx Biopharmaceuticals, Inc. (delisted) Chart

1 Month Keryx Biopharmaceuticals, Inc. (delisted) Chart

1 Month Keryx Biopharmaceuticals, Inc. (delisted) Chart

Your Recent History

Delayed Upgrade Clock